Skip to main content

Advertisement

SpringerLink
Log in

Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management

  • Endocrine Methods and Techniques
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

The detection of recurrent disease in differentiated thyroid cancer (DTC) patients with elevated or rising serum thyroglobulin (Tg) levels and multiple negative conventional imaging studies can be challenging, especially when 18F-FDG PET/CT scan is also negative. We report a patient and review the literature on the diagnostic use of 99mTc-sestamibi scans to identify the source of elevated or rising Tg in patients with negative conventional imaging including negative 18F-FDG PET/CT scans.

Patient and methods

A 73-year-old woman was referred for widely-invasive metastatic follicular thyroid cancer with bone metastasis to her left mandible. She had a total thyroidectomy, left mandibular resection, and 131I therapy of 145 mCi (5.4 GBq) and her subsequent unstimulated serum Tg level was 29 ng/ml (TgAb negative). At six months’ follow-up, her stimulated Tg was 527 ng/ml (TSH 188 mIU/L, TgAb negative). All imaging studies performed within the prior 12 months were reported as negative for recurrence or metastasis; this included neck ultrasound, diagnostic radioiodine scan, chest CT and, 18F-FDG PET/CT. The patient was injected with 24.6 mCi (910 MBq) of 99mTc-sestamibi intravenously, and whole-body and SPECT/CT images were acquired.

Results

The 99mTc-sestamibi whole-body posterior image demonstrated abnormal focal uptake in the right posterior calvarium and corresponded to an occipital lytic bone lesion on the SPECT/CT. The patient underwent surgical resection of the skull metastasis, and pathology confirmed metastatic follicular thyroid cancer. Five months post-surgery, the suppressed Tg was markedly reduced and remained stable at ~3.2 ng/ml. With the knowledge of the DTC recurrence location, the two sets of 18F-FDG images were re-evaluated. The more thorough and targeted interpretation underscored the importance of structured image reporting. The current literature on the utility of 99mTc-sestamibi scans when radioiodine, 18F-FDG PET/CT, and other imaging studies are negative is sparse and inconsistent.

Conclusions

99mTc-sestamibi may have a role in thyroid cancer localization when physical exam, neck ultrasound, radioiodine scan, chest/abdomen CT, and 18F-FDG PET/CT does not identify the source of elevated Tg levels in DTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. D. Rubello, G. Saladini, A. Carpi, D. Casara, Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan. Biomed. Pharmacother. 54(6), 337–344 (2000)

    Article  CAS  PubMed  Google Scholar 

  2. H. Elser, M. Henze, C. Hermann, W. Eckert, U. Mende, 99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nuklearmedizin 36(1), 7–12 (1997)

    Article  CAS  PubMed  Google Scholar 

  3. L. Wartofsky. Management of the patients with negative radioiodine scan and elevated serum thyroglobulin. Thyroid cancer: A Comprehensive Guide to Clinical Management. L. Wartofsky, D. Van Nostrand (eds) Springer, New York, NY), 2016) 529–538.

  4. F.X. Sundram, A.S. Goh, E.S. Ang, Role of technetium-99m sestamibi in localisation of thyroid cancer metastases. Ann. Acad. Med. Singap. 22(4), 557–559 (1993)

    CAS  PubMed  Google Scholar 

  5. S. Kosuda, H. Yokoyama, M. Katayama, T. Yokokawa, S. Kusano, O. Yamamoto, Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Eur. J. Nucl. Med. 22(10), 1218–1220 (1995)

    Article  CAS  PubMed  Google Scholar 

  6. J. Nemec, O. Nyvltova, T. Blazek, P. Vlcek, P. Racek, Z. Novak, M. Preiningerova, M. Hubackova, M. Krizo, J. Zimak, R. Bilek, Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur. J. Nucl. Med. 23(1), 69–71 (1996)

    Article  CAS  PubMed  Google Scholar 

  7. D.C. Ng, F.X. Sundram, A.E. Sin, 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J. Nucl. Med. 41(4), 631–635 (2000)

    CAS  PubMed  Google Scholar 

  8. O. Ugur, L. Kostakoglu, B. Caner, N. Guler, N.C. Gulaldi, M. Ozmen, U. Uysal, N. Elahi, G. Erbengi, C. Bejdik, Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma. Nucl. Med. Commun. 17(5), 373–377 (1996)

    Article  CAS  PubMed  Google Scholar 

  9. H. Elser, M. Henze, C. Hermann, W. Eckert, U. Mende, Follow-up of differentiated thyroid carcinoma by 99mTc-MIBI. Nukl. Arch. 36(1), 7–12 (1997)

    CAS  Google Scholar 

  10. S. Miyamoto, K. Kasagi, T. Misaki, M.S. Alam, J. Konishi, Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J. Nucl. Med. 38(3), 352–356 (1997)

    CAS  PubMed  Google Scholar 

  11. M.S. Alam, K. Kasagi, T. Misaki, S. Miyamoto, M. Iwata, Y. Iida, J. Konishi, Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation. Thyroid 8(12), 1091–1100 (1998)

    Article  CAS  PubMed  Google Scholar 

  12. S. Dadparvar, A. Chevres, M. Tulchinsky, L. Krishna-Badrinath, A.S. Khan, W.J. Slizofski, Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur. J. Nucl. Med. 22(11), 1330–1338 (1995)

    Article  CAS  PubMed  Google Scholar 

  13. A. Campenni, M.A. Violi, R.M. Ruggeri, A. Sindoni, M. Moleti, F. Vermiglio, S. Baldari, Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer. Nucl. Med. Commun. 31(4), 274–279 (2010)

    Article  PubMed  Google Scholar 

  14. T.C. Yen, H.D. Lin, C.H. Lee, S.L. Chang, S.H. Yeh, The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans. Eur. J. Nucl. Med. 21(9), 980–983 (1994)

    Article  CAS  PubMed  Google Scholar 

  15. A. Vattimo, P. Bertelli, M. Cintorino, L. Burroni, D. Volterrani, A. Vella, Identification of Hurthle cell tumor by single-injection, double-phase scintigraphy with technetium-99m-sestamibi. J. Nucl. Med. 36(5), 778–782 (1995)

    CAS  PubMed  Google Scholar 

  16. I.T. Zak, J.E. Seabold, N.J. Gurll, Tc-99m MIBI scintigraphic detection of metastatic insular thyroid carcinoma. Clin. Nucl. Med. 20(1), 31–36 (1995)

    Article  CAS  PubMed  Google Scholar 

  17. G. Zettinig, T. Leitha, B. Niederle, K. Kaserer, A. Becherer, K. Kletter, R. Dudczak, FDG positron emission tomographic, radioiodine, and MIBI imaging in a patient with poorly differentiated insular thyroid carcinoma. Clin. Nucl. Med. 26(7), 599–601 (2001)

    Article  CAS  PubMed  Google Scholar 

  18. D. Rubello, R. Mazzarotto, D. Casara, The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur. J. Nucl. Med. 27(4), 431–440 (2000)

    Article  CAS  PubMed  Google Scholar 

  19. D. Casara, D. Rubello, G. Saladini, R. Mazzarotto, G. Sotti, G. Tomasella, M.R. Pelizzo, Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole-body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography. Tumori 85(2), 122–127 (1999)

    CAS  PubMed  Google Scholar 

  20. C.H. Hsu, F.Y. Liu, R.F. Yen, C.H. Kao, Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr. Res. 29(1), 9–15 (2003)

    Article  PubMed  Google Scholar 

  21. N.O. Kucuk, H.A. Kulak, G. Aras, Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results. Ann. Nucl. Med. 20(6), 393–397 (2006)

    Article  PubMed  Google Scholar 

  22. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  23. H. Gharib, E. Papini, J.R. Garber, D.S. Duick, R.M. Harrell, L. Hegedus, R. Paschke, R. Valcavi, P. Vitti, American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules--2016 Update. Endocr. Pract. 22(5), 622–639 (2016)

    PubMed  Google Scholar 

  24. R.M. Tuttle, D.W. Ball, D. Byrd, R.A. Dilawari, G.M. Doherty, Q.-Y. Duh, H. Ehya, W.B. Farrar, R.I. Haddad, F. Kandeel, R.T. Kloos, P. Kopp, D.M. Lamonica, T.R. Loree, W.M. Lydiatt, J.C. McCaffrey, J.A. Olson, L. Parks, J.A. Ridge, J.P. Shah, S.I. Sherman, C. Sturgeon, S.G. Waguespack, T.N. Wang, L.J. Wirth, Thyroid Carcinoma. J. Natl. Compr. Cancer Netw. 8(11), 1228–1274 (2010)

    Article  Google Scholar 

  25. E. Silberstein, A. Alavi, H. Balon, D. Becker, N. Charkes, S. Clarke, C. Divgi, K. Donohoe, D, Delbeke, S. Goldsmith, Society of nuclear medicine procedure guideline for scintigraphy for differentiated papillary and follicular thyroid cancer. http://snmmi.files.cms-plus.com/docs/Scintigraphy%20for%20Differentiated%20Thyroid%20Cancer%20V3%200%20(9-25-06).pdf (2006). Accessed 28 Apr 2018.

  26. F. Grunwald, C. Menzel, H. Bender, H. Palmedo, P. Willkomm, J. Ruhlmann, T. Franckson, H.J. Biersack, Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7(3), 327–335 (1997)

    Article  CAS  PubMed  Google Scholar 

  27. M. Dietlein, K. Scheidhauer, E. Voth, P. Theissen, H. Schicha, Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 37(1), 12–17 (1998)

    Article  CAS  PubMed  Google Scholar 

  28. L. Fridrich, C. Messa, C. Landoni, G. Lucignani, R. Moncayo, D. Kendler, G. Riccabona, F. Fazio, Whole-body scintigraphy with 99Tcm-MIBI, 18F-FDG and 131I in patients with metastatic thyroid carcinoma. Nucl. Med. Commun. 18(1), 3–9 (1997)

    Article  CAS  PubMed  Google Scholar 

  29. F. Grunwald, T. Kalicke, U. Feine, R. Lietzenmayer, K. Scheidhauer, M. Dietlein, O. Schober, H. Lerch, K. Brandt-Mainz, W. Burchert, G. Hiltermann, U. Cremerius, H.J. Biersack, Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur. J. Nucl. Med. 26(12), 1547–1552 (1999)

    Article  CAS  PubMed  Google Scholar 

  30. M. Iwata, K. Kasagi, T. Misaki, K. Matsumoto, Y. Iida, T. Ishimori, Y. Nakamoto, T. Higashi, T. Saga, J. Konishi, Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 31(4), 491–498 (2004)

    Article  CAS  PubMed  Google Scholar 

  31. D. Rubello, M. Salvatori, D. Casara, A. Piotto, A. Toniato, M.D. Gross, A. Al-Nahhas, P.C. Muzzio, M.R. Pelizzo, 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur. J. Surg. Oncol. 33(7), 902–906 (2007)

    Article  CAS  PubMed  Google Scholar 

  32. K. Leung, (99m)Tc-2-Methoxyisobutylisonitrile. In: Molecular Imaging and Contrast Agent Database (MICAD) (National Center for Biotechnology Information (US), Bethesda, MD, 2004). https://www.ncbi.nlm.nih.gov/books/NBK23098/.

  33. R. Czepczyński, M. Gryczyńska, M. Ruchała, 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment. Nucl. Med. Rev. 19(2), 67–73 (2016)

    Article  Google Scholar 

  34. M. Ocak, E. Demirci, L. Kabasakal, A. Aygun, R.O. Tutar, A. Araman, B. Kanmaz, Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl. Med. Commun. 34(11), 1084–1089 (2013)

    Article  CAS  PubMed  Google Scholar 

  35. C.J. Edmonds, S. Hayes, J.C. Kermode, B.D. Thompson, Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br. J. Radiol. 50(599), 799–807 (1977)

    Article  CAS  PubMed  Google Scholar 

  36. J. Lee, M.J. Yun, K.H. Nam, W.Y. Chung, E.Y. Soh, C.S. Park, Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20(2), 173–179 (2010)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This manuscript was underwritten by donations from grateful patients.

Author information

Authors and Affiliations

  1. MedStar Clinical Research Center, MedStar Health Research Institute, 6525 Belcrest Road #700, Hyattsville, MD, 20782, USA

    Di Wu, Dorina Ylli, Cristiane J. Gomes Lima, Leonard Wartofsky & Douglas Van Nostrand

  2. Nuclear Medicine Research, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC, 20010, USA

    Di Wu & Douglas Van Nostrand

  3. Division of Endocrinology, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC, 20010, USA

    Dorina Ylli, Cristiane J. Gomes Lima, Kenneth D. Burman & Leonard Wartofsky

  4. Department of Pathology, MedStar Washington Hospital Center, 110 Irving St NW, Suite BB-21B, Washington, DC, 20010, USA

    Wen Lee

Authors
  1. Di Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorina Ylli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristiane J. Gomes Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth D. Burman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leonard Wartofsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Douglas Van Nostrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Van Nostrand.

Ethics declarations

Informed consent

For this case report formal consent is not required.

Conflict of interest

D.VN.: Speaker and consultant for Jubilant DraxImage and Genzyme. L.W.: Speaker for Genzyme. The other authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, D., Ylli, D., Gomes Lima, C.J. et al. Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management. Endocrine 62, 57–63 (2018). https://doi.org/10.1007/s12020-018-1636-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-018-1636-y

Key words

Search

Navigation